CancerDrs Find care

Leukemia clinical trials

300 actively recruiting leukemia trials in the United States. Cancers of the blood and bone marrow. Clinical trial participation is historically higher for leukemia than most solid tumors.

Data from ClinicalTrials.gov · last refreshed · Leukemia stats on SEER

83
Phase 1
122
Phase 2
13
Phase 3
4
Phase 4
78
Other

Leukemia by the numbers (U.S.)

66,890
Estimated new cases (2025)
23,540
Estimated deaths (2025)
67.8%
5-year relative survival
68
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse leukemia trials by state

Texas 105 California 90 New York 87 Ohio 77 Florida 72 Massachusetts 62 North Carolina 56 Pennsylvania 51 Washington 51 Illinois 44 Tennessee 44 Maryland 43 Georgia 42 Oregon 40 Wisconsin 38 Minnesota 37 Missouri 35 Colorado 34 Michigan 33 Virginia 33 Arizona 30 Alabama 26 Utah 25 New Jersey 24 Connecticut 23 Indiana 20 Kentucky 19 Oklahoma 19 South Carolina 17 Louisiana 16 Arkansas 15 Iowa 15 Nebraska 14 Kansas 13 Rhode Island 12 District of Columbia 11 Maine 11 Mississippi 11 Nevada 11 West Virginia 10 Delaware 9 Hawaii 9 Idaho 9 South Dakota 9 New Hampshire 8 New Mexico 7 Vermont 7 Montana 6 Alaska 5 North Dakota 5

Top trials by phase + site coverage

Phase 3 Recruiting Network

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care …

Sponsor: Children's Oncology Group
NCT ID: NCT05602194
Locations:
  • Children's Hospital of Alabama — Birmingham, Alabama
  • Providence Alaska Medical Center — Anchorage, Alaska
  • Kingman Regional Medical Center — Kingman, Arizona

+ 223 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…

Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Locations:
  • City of Hope Phoenix — Goodyear, Arizona
  • Mayo Clinic - Phoenix — Phoenix, Arizona
  • University of Arizona Cancer Center — Tucson, Arizona

+ 49 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…

Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Locations:
  • Phoenix Children's Hospital — Phoenix, Arizona
  • Arkansas Children's Hospital — Little Rock, Arkansas
  • MemorialCare Miller Children's and Women's Hospital Long Beach — Long Beach, California

+ 41 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Locations:
  • USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
  • Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona

+ 38 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…

Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Locations:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • University of California, Fresno — Clovis, California
  • University of California, San Diego — La Jolla, California

+ 31 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Locations:
  • City of Hope Cancer Center — Duarte, California
  • University of California San Diego Medical Center — La Jolla, California
  • University of California Los Angeles — Los Angeles, California

+ 29 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…

Sponsor: AbbVie
NCT ID: NCT06428019
Locations:
  • Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
  • Southern VA Health Care System /ID# 266254 — Tucson, Arizona
  • UCSF FRESNO/Community Cancer Institute /ID# 270874 — Clovis, California

+ 29 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at es…

Sponsor: Taiho Oncology, Inc.
NCT ID: NCT04256317
Locations:
  • Keck School of Medicine of USC — Los Angeles, California
  • UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
  • Yale University — New Haven, Connecticut

+ 21 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…

Sponsor: BeOne Medicines
NCT ID: NCT06846671
Locations:
  • St Bernards Medical Center — Jonesboro, Arkansas
  • UCLA Department of Medicine Hematologyoncology — Los Angeles, California
  • Pih Health Whittier Hospital — Whittier, California

+ 17 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations:
  • Pacific Cancer Medical Center, Inc — Anaheim, California
  • TOI Clinical Research — Cerritos, California
  • Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California

+ 16 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrut…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05947851
Locations:
  • Highlands Oncology Group ( Site 5405) — Springdale, Arkansas
  • MemorialCare Health System - Long Beach Medical Center ( Site 5421) — Long Beach, California
  • Memorial Hospital West ( Site 5410) — Pembroke Pines, Florida

+ 3 more sites in the U.S.

View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Sponsor: Quetzal Therapeutics
NCT ID: NCT07504458
Locations:
  • Quetzal Site 1 — Duarte, California
  • Quetzal Site 4 — Buffalo, New York
  • Quetzal Site 2 — The Bronx, New York

+ 1 more site in the U.S.

View on ClinicalTrials.gov →

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20